Takeda Pharmaceutical Company Limited (TAK) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Tokyo, Japan. Le PDG actuel est Christophe Weber.
TAK a date d'introduction en bourse 2010-01-05, 49,281 employés à temps plein, cotée sur le NYSE, une capitalisation boursière de $56.39B.
Takeda Pharmaceutical Company Limited is a globally diversified pharmaceutical company headquartered in Tokyo, Japan, with operations across North America, Europe, Latin America, Russia, and Asia. Founded in 1781, Takeda engages in the research, development, manufacturing, and commercialization of pharmaceutical products across key therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company markets numerous branded products such as Entyvio, Velcade, Adcetris, and Trintellix, and maintains an extensive portfolio of strategic collaborations and licensing agreements with leading biotech firms and research institutions to support its pipeline development and innovation initiatives.
